FactSet Research Systems announced the beta release of its AI‑Powered Document Ingest for the Cobalt portfolio‑monitoring platform on February 4 2026, adding a new layer of automation to its private‑capital suite.
The new tool automatically extracts, validates, and publishes structured data from PDFs, Excel files, board decks, and other source documents. It requires no client‑side training, allowing early beta users to cut manual reconciliation time from days to minutes and to generate more accurate, AI‑ready data sets for downstream analytics.
By embedding the capability directly into Cobalt, FactSet seeks to deepen workflow integration, increase client stickiness, and create a new revenue stream within its private‑capital offering. The launch is part of a broader AI strategy that includes the company’s GenAI model and FactSet Mercury, underscoring a focus on automation and conversational intelligence across its product lines.
Emily Monaghan, Senior Vice President and Senior Director of Private Capital, said the solution tackles the “fragmented, manual portfolio data collection” that has long plagued private‑equity, growth, venture, and credit firms. She added that the AI‑driven ingestion “automates data extraction and ingestion, reflecting our commitment to innovation and helping clients unlock greater accuracy, transparency, and efficiency in their reporting and investment workflows.”
The product addresses a key pain point in the private‑capital market: the time‑consuming, error‑prone process of gathering and reconciling data from disparate sources. By delivering near‑real‑time, AI‑ready data, FactSet positions itself to capture a larger share of the growing demand for data‑driven decision making in private markets, while reinforcing its competitive advantage over firms that still rely on legacy, manual workflows.
FactSet’s Q1 2026 earnings, reported earlier in December, showed revenue of $607.6 million and an adjusted EPS of $4.51, indicating a solid financial foundation for the company to invest in new AI capabilities. The AI‑Doc Ingest launch adds a scalable, high‑margin product to the portfolio, aligning with the company’s strategy to grow revenue through technology‑enabled services rather than traditional licensing or consulting fees.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.